245 related articles for article (PubMed ID: 24125101)
81. Association between CYP2D6 polymorphisms and breast cancer outcomes.
Lash TL
JAMA; 2010 Feb; 303(6):516; author reply 517. PubMed ID: 20145226
[No Abstract] [Full Text] [Related]
82. Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records.
Thorén L; Margolin S; Eliasson E; Bergh J; Lindh JD
Breast Cancer Res Treat; 2023 Apr; 198(3):499-508. PubMed ID: 36856936
[TBL] [Abstract][Full Text] [Related]
83. Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.
Hertz DL; Deal A; Ibrahim JG; Walko CM; Weck KE; Anderson S; Magrinat G; Olajide O; Moore S; Raab R; Carrizosa DR; Corso S; Schwartz G; Graham M; Peppercorn JM; Jones DR; Desta Z; Flockhart DA; Evans JP; McLeod HL; Carey LA; Irvin WJ
Oncologist; 2016 Jul; 21(7):795-803. PubMed ID: 27226358
[TBL] [Abstract][Full Text] [Related]
84. Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy.
Zhang X; Pu Z; Ge J; Shen J; Yuan X; Xie H
Med Sci Monit; 2015 Feb; 21():563-9. PubMed ID: 25701109
[TBL] [Abstract][Full Text] [Related]
85. CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines.
Drögemöller BI; Wright GEB; Shih J; Monzon JG; Gelmon KA; Ross CJD; Amstutz U; Carleton BC;
Breast Cancer Res Treat; 2019 Feb; 173(3):521-532. PubMed ID: 30411242
[TBL] [Abstract][Full Text] [Related]
86. Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: A propensity-score matched cohort study.
Zhou W; Jiang Y; Xu Y; Wang Y; Ma X; Zhou L; Lin Y; Wang Y; Wu Z; Li M; Yin W; Lu J
Int J Cancer; 2022 May; 150(10):1664-1676. PubMed ID: 34957551
[TBL] [Abstract][Full Text] [Related]
87. Genetic polymorphisms of CYP2D6 10 and CYP2C19 2, 3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen.
Okishiro M; Taguchi T; Jin Kim S; Shimazu K; Tamaki Y; Noguchi S
Cancer; 2009 Mar; 115(5):952-61. PubMed ID: 19156902
[TBL] [Abstract][Full Text] [Related]
88. Pharmacogenomics of endocrine therapy in breast cancer.
Weinshilboum R
Adv Exp Med Biol; 2008; 630():220-31. PubMed ID: 18637494
[TBL] [Abstract][Full Text] [Related]
89. Early increase in tamoxifen dose in CYP2D6 poor metaboliser breast cancer patients and survival: A propensity score matching analysis.
Blancas I; Linares-Rodríguez M; Martínez de Dueñas E; Herrero-Vicent C; Molero-Mir MD; Garrido JM; Rodríguez-Serrano F
Breast; 2023 Jun; 69():342-348. PubMed ID: 37011481
[TBL] [Abstract][Full Text] [Related]
90.
Ramírez G; Vital M; Vergara C; Carusso F; Neffa F; Valle AD; Esperón P
Per Med; 2023 Nov; 20(6):477-483. PubMed ID: 37947089
[No Abstract] [Full Text] [Related]
91. Should CYP2D6 be genotyped when treating with tamoxifen?
Del Re M; Rofi E; Citi V; Fidilio L; Danesi R
Pharmacogenomics; 2016 Dec; 17(18):1967-1969. PubMed ID: 27883289
[No Abstract] [Full Text] [Related]
92. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
Goetz MP; Kamal A; Ames MM
Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
[TBL] [Abstract][Full Text] [Related]
93. Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients.
Damkier P
Pharmacogenomics; 2017 Jun; 18(8):753-754. PubMed ID: 28592184
[TBL] [Abstract][Full Text] [Related]
94. Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance.
Goetz MP; Suman VJ; Couch FJ; Ames MM; Rae JM; Erlander MG; Ma XJ; Sgroi DC; Reynolds CA; Lingle WL; Weinshilboum RM; Flockhart DA; Desta Z; Perez EA; Ingle JN
Clin Cancer Res; 2008 Sep; 14(18):5864-8. PubMed ID: 18794098
[TBL] [Abstract][Full Text] [Related]
95. The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen.
Sanchez-Spitman AB; Moes DA; Gelderblom H; Dezentjé VO; Swen JJ; Guchelaar HJ
Pharmacogenomics; 2017 Aug; 18(12):1125-1132. PubMed ID: 28745555
[TBL] [Abstract][Full Text] [Related]
96. Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation.
Yu KD; Huang AJ; Shao ZM
PLoS One; 2010 Dec; 5(12):e15649. PubMed ID: 21187922
[TBL] [Abstract][Full Text] [Related]
97. Determination of CYP2D6 *3, *4, and *10 frequency in women with breast cancer in São Luís, Brazil, and its association with prognostic factors and disease-free survival.
Martins DM; Vidal FC; Souza RD; Brusaca SA; Brito LM
Braz J Med Biol Res; 2014 Nov; 47(11):1008-15. PubMed ID: 25296365
[TBL] [Abstract][Full Text] [Related]
98. The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
Lan B; Ma F; Zhai X; Li Q; Chen S; Wang J; Fan Y; Luo Y; Cai R; Yuan P; Zhang P; Li Q; Xu B
Int J Cancer; 2018 Jul; 143(1):184-189. PubMed ID: 29396856
[TBL] [Abstract][Full Text] [Related]
99. [CYP2D6 polymorphisms and tamoxifen: therapeutic perspectives in the management of hormonodependent breast cancer patients].
Barrière J; Formento JL; Milano G; Ferrero JM
Bull Cancer; 2010 Mar; 97(3):311-20. PubMed ID: 20123649
[TBL] [Abstract][Full Text] [Related]
100. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen?
Zembutsu H; Sasa M; Kiyotani K; Mushiroda T; Nakamura Y
Expert Rev Anticancer Ther; 2011 Feb; 11(2):185-93. PubMed ID: 21342038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]